Sign up for news & promotions:
ULBP1 Primary Antibody
|Aliases||N2DL-1; RAET1I; NKG2DL1|
|Formulation||Purified antibody in PBS with 0.05% sodium azide|
|Immunogen||Purified recombinant fragment of human ULBP1 (AA: 26-216) expressed in E. Coli.|
|FCM (Flow Cytometry)||1/200 - 1/400|
|WB (Western Blot)||1/500 - 1/2000|
Figure 1:Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)
Figure 2:Western blot analysis using ULBP1 mAb against human ULBP1 (AA: 26-216) recombinant protein. (Expected MW is 48.3 kDa)
Figure 3:Western blot analysis using ULBP1 mAb against HEK293 (1) and ULBP1 (AA: 26-216)-hIgGFc transfected HEK293 (2) cell lysate.
Figure 4:Flow cytometric analysis of Hela cells using ULBP1 mouse mAb (green) and negative control (red).
The protein encoded by this gene is a ligand of natural killer group 2, member D (NKG2D), an immune system-activating receptor on NK cells and T-cells. Binding of the encoded ligand to NKG2D leads to activation of several signal transduction pathways, including those of JAK2, STAT5, ERK and PI3K kinase/Akt. Also, in cytomegalovirus-infected cells, this ligand binds the UL16 glycoprotein and is prevented from activating the immune system. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2015]
|References (references)||1.Oncotarget. 2016 Mar 29;7(13):15369-81. 2.Elife. 2015 Nov 13;4. pii: e08474.|